/
We are a clinical stage biotechnology company fully dedicated to developing IL-1 -based treatments for immune-mediated inflammatory diseases. Our lead product candidate, abdakibart (AVTX-009), an anti-IL-1 monoclonal antibody ( mAb ) is in a Phase 2 clinical trial for hidradenitis suppurativa ( HS ).
The business is unprofitable at the operating level (-123601.69% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 86.6% YoY. Margins deteriorated 108066.1pp alongside, both lines moving the wrong way.
Negative free cash flow of -$59M. The business is consuming cash, not generating it. Operating margin contracted 108066.1pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (FY)
$59K
▼ -86.6% YoY
Net Income (TTM)
-$85M
▼ -122.8% YoY
Op. Margin
-123601.69%
▼ -108066.1pp YoY
ROIC
-71.57%
▲ +22.6pp YoY
Cash Flow & Balance Sheet
FCF (FY)
-$59M
▼ -20.2% YoY
Op. Cash Flow (TTM)
-$60M
▼ -4.9% YoY
Net Debt
-$82M
Net Cash Position
Cash & Equiv.
$82M
5Y CAGR: -61.2%
Continue Research